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Abstract
Background: Primary care clinicians will see a higher incidence of type 2 diabetes in adult patients, and the
diagnosis and management of an initial presentation of type 1 diabetes can pose challenges to clinicians who see
it less frequently. Symptoms of hyperglycemia and risk of ketoacidosis may be missed. Further, endocrine
autoimmune disease can run together in patients and families.
Case presentation: A 49-year-old Caucasian female with history of pituitary adenoma and Graves’ disease with
history of thyroid ablation presented in the outpatient setting due to hand tingling of her right middle finger that
was worse in the mornings and improved throughout the day. She also complained of excessive thirst, finding
herself drinking more water than usual and waking up in the night to urinate. There was no dysuria or haematuria,
and no other neurologic symptoms. She did report feeling hungry. She had no family history of diabetes, normal
body mass index of 21.7, and reported taking her thyroid replacement medication every day. The differential
diagnosis for her thirst included dehydration, psychogenic polydipsia, diabetes mellitus, diabetes insipidus, and
anxiety. The patient had normal vital signs and was well appearing; labs were ordered for her on her way home
from clinic with no medications. Labs revealed a random blood glucose level of 249 mg/dL, normal renal function,
a normal B12 of 996 pg/mL, and an elevated thyroid stimulating hormone level of 25.67 u[iU]/mL. On follow up
with her primary care provider 5 days later, additional labs were drawn showing A1C of 11.5%, 1+ ketonuria, a
negative Acetest, and a normal basic metabolic panel, except for a fasting glucose of 248 mg/dL, and Free T3 of 2.
42 pg/mL, and Free T4 of 1.7 ng/dL. Islet cell antibodies and glutamic acid decarboxylase antibodies were both
positive, consistent with type 1 diabetes. She was started on insulin and improved.
Conclusion: Given the patient’s age, this is a less common presentation of type 1 diabetes mellitus, as a part of
polyglandular autoimmune syndrome type IIIa. It serves as a reminder that clinicians should remember that patients
with one autoimmune disease (in this case, h/o Graves’ disease) are at higher risk for diabetes and other endocrine
autoimmune diseases and should be screened appropriately. Clinicians should keep latent type 1 diabetes in the
differential in adulthood to ensure proper and timely treatment.
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Diabetic ketoacidosis
Background
While diabetes is an extremely common disease, most
primary care clinicians will see more type 2 diabetes in
adult patients, and the diagnosis and management of an
initial presentation of type 1 diabetes can pose chal-
lenges to clinicians who see it less frequently. This case
offers a reminder that a random blood glucose over 200
and classic hyperglycemic symptoms of polyuria, poly-
dypsia, and nocturia were sufficient for the diagnosis of
diabetes at the patient’s initial visit, whereas in the
absence of unequivocal hyperglycemia, a test diagnostic
of diabetes should be confirmed by repeat testing [1].
Additionally, this patient was at higher risk for type 1
diabetes given her history of Graves’ disease, an import-
ant relationship for clinicians to recognize [2]. While the
majority of patients in her age group present with type 2
diabetes, she presented with classic symptoms of type 1
diabetes [3].
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Type 1 diabetes is autoimmune in 95% of cases (type
1a) and idiopathic in under 5% of cases (type 1b). While
type 1 diabetes can present at any age, peaks in inci-
dence occur before school age and again around puberty
[4]. Given that autoimmune destruction of beta cells has
multiple genetic predispositions, patients with other
autoimmune disorders such as Hashimoto’s thyroiditis,
Graves’ disease, Addison’s disease, celiac disease, auto-
immune hepatitis, and myasthenia gravis, should be
screened for type 1 diabetes [1, 5, 6].
A coexistence of at least two autoimmune-mediated
endocrinopathies is classified as polyglandular auto-
immune syndromes (PAS). Autoimmune thyroid disor-
ders represent the most frequent autoimmune
endocrinopathies within PAS and with a prevalence of
70 to 75%. The second most common endocrine auto-
immune condition in the adult PAS patient is type 1 dia-
betes and is present in 50 to 60% of these patients [6].
Type 1 diabetes is defined by fasting glucose >126 mg/
dL or postprandial glucose >200 mg/dL or hemoglobin
A1c over 6.5% and insulin deficiency as well as clinical
signs of an insulin deficiency syndrome (polyuria, poly-
dipsia, weight loss, ketoacidosis). According to the
American Diabetes Association, blood glucose rather
than an A1c should be used to diagnose type 1 diabetes
in patients with symptoms of hyperglycemia. Type 1 dia-
betes is defined by the presence of one or more
diabetes-associated autoimmune markers, such as islet
cell antibody (ICA) and glutamic acid decarboxylase
antibody (GADA). If a new diagnosis of type 1 diabetes
is suspected, diabetic ketoacidosis should be ruled out at
the initial clinical presentation, given 25% of type 1 dia-
betes patients present in diabetic ketoacidosis [1, 5].
The degree of beta cell destruction in patients with
type 1 diabetes is variable, although it is often consid-
ered more rapid in younger patients and slower in
adults. Older adults can frequently present with a more
indolent onset of type 1 diabetes, which may lead to
misdiagnosis as type 2 diabetes. This particular case
presentation is referenced by the term latent auto-
immune diabetes of adulthood (LADA). LADA is de-
fined by three criteria identified by the Immunology of
Diabetes Society including adult age of onset (>30 years
of age), presence of at least one circulating autoantibody
(GADA/ICA/IAA/IA-2), and initial insulin independ-
ence (within the first 6 months) [7, 8].
Although LADA has similar genetic and immunologic
features as juvenile-onset type 1 diabetes, it also em-
bodies some characteristics of type 2 diabetes. At diag-
nosis, insulin secretion is often similar in patients with
LADA and type 2 diabetes. These patients may have
enough beta cell function that they may be controlled
with oral medicines and diet initially, but over time
develop increasing dependence on insulin therapy, and
thus often require insulin earlier than would otherwise be
expected in a type 2 diabetic. Compared to type 2 dia-
betes, patients with LADA require insulin treatment earl-
ier and more commonly post diagnosis and show worse
glycemic control than type 2 diabetes patients [7, 8].
Importantly, type 1 diabetes involves the progressive
destruction of beta cells and therefore lower insulin
levels, which predisposes these patients to developing
ketoacidosis, often leading to pronounced hypergly-
cemia, and necessitates prompt treatment [3]. These
patients have different treatment considerations than
those with type 2 diabetes, and they more often present
with complications like diabetic ketoacidosis [3]. This
patient was not in ketoacidosis, but the lack of full
evaluation on initial presentation delayed proper and
timely treatment, which would have been a significant
mistake had she been acidotic. It is important for clini-
cians to screen at risk patients as well as diagnose and
manage type 1 diabetes efficiently even when it presents
in an atypical fashion.
Case presentation
This 49-year-old patient presented with a chief complaint
of recent onset finger tingling, and also complained of
excessive thirst, which was most pronounced at night.
Although she normally did not drink much water, she was
drinking about 1 gal of water per night. Additionally, she
reported frequent urination, having to wake up six to eight
times per night to urinate. She also reported being hungry
after dinner, which was abnormal for her. She denied nau-
sea or vomiting. The patient had no known family history
of diabetes, but did have personal history of pituitary
adenoma (diagnosed at age 18 without progression) and
history of Graves’ disease with history of thyroid ablation
10 years previously. Her only other past history included
biceps tendonitis and left shoulder pain. Her medications
included levothyroxine 137mcg 4 days per week and
125mcg 3 days per week. She reported that on the days
when she took 137 mcg of levothyroxine, she noticed her
heart beating faster. She was very physically active as part
of her job as a fitness instructor, and she reported feeling
as though she might pass out when she was kneeling
down and then standing up.
Objectively, patient’s BMI at presentation was 21.7 kg/
m2. She lost 1.27 kg in the 10 days prior to presentation
to clinic. Her heart rate was 96 beats per minute. Other-
wise, her physical exam was unremarkable.
This patient had multiple features suggesting that she
should be tested for autoantibodies, which would help to
confirm the diagnosis of type 1 diabetes. These features
included age of onset <50 years, acute symptoms, BMI
<25, and personal or family history of autoimmune dis-
ease [4]. Some clinicians measure two antibodies (glu-
tamic acid decarboxylase and islet cell antibodies), and
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especially if both antibodies are positive, the patient
should be presumed to have type 1 diabetes and often
initiated on insulin [4, 5, 9].
About 25% of adults newly diagnosed with type 1 dia-
betes can be in diabetic ketoacidosis [3]. Thus, this
should be ruled out at initial presentation in patients
presenting with an insulin deficiency syndrome. While
this ideally would have been done at the patient’s initial
visit when she was found to be hyperglycemic, further
testing was not performed at that time. At the patient’s
follow up visit five days later, a basic metabolic panel
was done, which ruled out an anion gap metabolic acid-
osis, and a urinalysis was performed, which confirmed
glucosuria and ketonuria. An Acetest (nitroprusside
reaction to measure levels of serum acetone and acetate)
was done to rule out serum ketone production, and this test
was negative. This test is limited in evaluation for serum
ketones because it does not test for beta-hydroxybuturate,
another serum ketone produced in DKA. However, at our
institution, testing for beta-hydroxybutyrate does not result
for 2–3 days, thus it would have been unlikely to change
our initial management.
The patient’s ICA was 0.06 nmol/L (reference range
< =0.02 nmol/L) and GADA was 2.81 (reference
range < =0.02 nmol/L). Of note, GADA is often used
interchangeably with glutamic acid decarboxylase 65
(GAD 65). In newly diagnosed patients with type 1 dia-
betes, GADA has a sensitivity of 70–90% and specificity
99% for the diagnosis, and islet cell antibody testing has a
sensitivity of 44–100% and specificity of 96% [10]. Also,
GAD 65 has a positive predictive value of 92% for requir-
ing insulin at three years in persons 15 to 34 years of age,
and ICA has a positive predictive value of 86% for requir-
ing insulin at three years in persons 15 to 34 years of age
[11]. Thus, each of these tests confers an increased likeli-
hood of requiring insulin. In addition, the magnitude of
the insulin response is inversely proportional to the GAD
levels [7].
Given the near total deficiency of insulin and subse-
quent risk of ketoacidosis, insulin is often initiated at
diagnosis and is considered the mainstay of therapy for
patients with type 1 diabetes. For patients with type 1
diabetes, the goal of insulin therapy is to provide a
physiologic profile of insulin by giving a daily (or twice
daily) long acting insulin preparation as well as pre-
meal boluses of a rapid acting insulin. Our patient
was started on long acting insulin glargine 10 units at
night and rapid acting insulin lispro 2 units with
breakfast, lunch, and dinner. Initial total insulin dose
in type 1 diabetic patients is 0.2 to 0.6 units/kg/day,
but in order to avoid complications of hypoglycemia,
it is reasonable to start with 0.2–0.4 units/kg/day.
Thus, our patient was started on approximately
0.3 units/kg/day of insulin in total [5, 9, 12].
With an insulin regimen of insulin glargine and lispro
before meals, her Hemoglobin A1c came down to 7.6%
over the next 9 months. She was started on a statin and
aspirin for cardiovascular risk reduction. At one year
after presentation, her treatment team included her pri-
mary care physician, endocrinologist, nutritionist, and
pharmacist. Her medication regimen was insulin glargine
10 units/sc at night, insulin lispro 3 units before meals,
Atorvastatin 10 mg daily, and aspirin 81 mg daily. Self-
monitoring glucose was a 7-day average of 139 mg/dL
and a 14-day of average 144 mg/dL.
Discussion and conclusions
Diabetes was at the top of the differential diagnosis list
upon presentation. This patient was likely to have type 1
diabetes at presentation, as defined by fasting glucose
>126 or postprandial glucose >200, or hemoglobin A1c
of 6.5% or greater and insulin deficiency, as well as clin-
ical signs of an insulin deficiency syndrome (polyuria,
polydipsia, weight loss, ketoacidosis [8]. We had discov-
ered all of these features by the time of her follow up
visit, except testing for C-peptide was not done for insu-
lin deficiency. The patient’s polyphagia with weight loss
and nocturnal enuresis are all clinical features of type 1
diabetes at diagnosis and not type 2 diabetes. The pa-
tient’s report of presyncopal symptoms also fit with vol-
ume depletion caused by osmotic diuresis due to
hyperglycemia. In contrast, patients with type 2 diabetes
are often asymptomatic at presentation [13].
Another diagnostic consideration was overtreatment
of her hypothyroidism. Her weight loss, increased appe-
tite, urinary frequency, and more rapid heartbeat could
have been explained by hyperthyroidism [14]. However,
her elevated TSH was consistent with under treatment
and subsequent free T-4 was normal.
In a patient with multiple autoimmune diseases, the
clinician should have a higher index of suspicion that
the patient could present with an additional auto-
immune disease. Our patient could be classified as hav-
ing one of the polyglandular autoimmune syndromes
(PAS), specifically PAS IIIa [6, 15]. These syndromes are
divided into PAS I, II, and III. While juvenile PAS I is
quite rare, PAS II commonly presents in the third or
fourth decade in women, and has a prevalence of
1:20,000. The main difference between PAS III and PAS
II is the absence of adrenal cortical involvement causing
adrenal insufficiency in PAS III, while this is present in
PAS II. Autoimmune thyroiditis (Graves’ disease or
Hashimoto’s thyroiditis) and type 1 diabetes, when oc-
curring together, are defined as autoimmune polyglandu-
lar syndrome type IIIa [15]. Notably, there is often a
long time interval between the manifestation of the first
and second component disease of PAS II, which often
comprises years to decades. Perhaps our patient may
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later develop adrenal insufficiency given she has both
type 1 diabetes and autoimmune thyroid disease, which
may suggest an underlying genetic predisposition to PAS
II. PAS II can also include features of adrenal insuffi-
ciency, hypoparathyroidism, primary hypogonadism, and
other manifestations [6]. Clinicians need to be on the
lookout for these associated diseases [6, 16, 17].
Experts recommend serologic and functional screening
for these associated diseases in patients with a mono-
glandular autoimmune disease at diagnosis and during
follow-up appointments at least every 2 years [6, 16].
Although diabetes-associated autoantibodies can be
obtained to predict individuals at risk for developing
type 1 diabetes, methods to delay or prevent disease on-
set are not promising. Immunosuppressive agents (such
as cyclosporine, rituximab, abatacept), which come with
a variety side effects, have been evaluated to prevent or
delay type 1 diabetes and shown limited to no impact.
For the few drugs that appear to have some effect, not
all patients respond and for those who do, the effects are
often short-lived. Although there is limited evaluation of
beta-cell prevention or preservation in LADA patients,
one study using a GAD-alum formulation demonstrated
a relative preservation of C-peptide release for 5 years, with
limited side effects. Still, the benefit of screening diabetes-
associated autoantibodies prior to diagnosis remains con-
troversial [7, 18]. Given that our patient has type 1 diabetes
and thyroid disease, screening may include functional
assessment of adrenal failure, primary hypogonadism,
hypoparathyroidism, type A autoimmune gastritis with or
without pernicious anemia, and celiac disease.
After identification of autoimmune thyroid disease,
screening for diabetes (such as oral glucose tolerance test-
ing) should have been implemented and could have led to
earlier detection in our patient. Our patient was started on
insulin at diagnosis and given that her presentation was
more consistent with type 1 diabetes versus early onset
LADA. Insulin is often started in patients who have weight
loss or dehydration in the setting of hyperglycemia or if
they have evidence of increased ketogenesis as evidenced
by ketonuria or acidosis; our patient met all of these criteria
aside from the acidosis and thus we started her on insulin
[4, 9]. Interestingly, our patient may have had LADA for
years before this clinical presentation, causing her beta cell
mass to decrease, which resulted in having more features of
type 1 diabetes than other adult patients with LADA, who
do not require insulin at diagnosis [4, 7]. Previously, a blood
glucose had not been checked to screen for diabetes. If her
clinicians had been more mindful of the relationship
between autoimmune thyroid disease and diabetes, perhaps
they would have checked her blood sugar sooner (despite
her appearance as a fit, healthy female), diagnosed LADA,
and potentially delayed her progression to insulin depend-
ence through early treatment.
Due to the paucity of data, the optimal initial treat-
ment of latent autoimmune diabetes in adults (LADA) is
not established. Studies treating recently-diagnosed
LADA patients with dipeptidyl peptidase 4 (DPP-4) in-
hibitors suggest that these may postpone loss of beta cell
function, although these findings are not convincing and
need to be confirmed in larger randomized trials.
Despite its widespread use in type 2 disease, there are no
studies evaluating the impact of metformin alone in
patients with LADA. However, use of sulfonylureas is
discouraged due to rapid deterioration of beta cells [7].
To date, the evidence suggests that patients with LADA
should be initially treated with insulin when glycemic
control declines to a level indicating need for antidia-
betic treatment [7, 19].
Unfortunately, treatment of T1DM remains an on-
going challenge. Tight control with intensive insulin
treatment leading to reduced complications is often hin-
dered by increased hypoglycemia and weight gain.
Physiologic insulin strategies with rapid-acting analog
insulins and insulin pumps combined with continuous
glucose monitoring systems have shown improved
glycemic control and decreased side effects. Use of ad-
junctive therapies, with non-insulin therapies, can be
considered for patients with type 1 diabetes failing to
achieve glycemic control on insulin [5, 9, 20].
Pramlintide, an amylin analog, is the only FDA-
approved adjunctive therapy for type 1 diabetes. Use is
limited due to concerns with tolerability and the need
for administration by multiple daily injections or an
infusion pump [5, 20]. Evidence suggests that adding
metformin to insulin therapy may reduce insulin doses
and improve metabolic control in overweight type 1 dia-
betic patients [20, 21]. Promising data is available for
glucagon-like peptide 1 (GLP-1) receptor agonists and
dipeptidyl peptidase 4 (DPP-4) inhibitors due to their
potential protection of beta cells and suppression of glu-
cagon release [20]. More clinical data exist for GLP-1 ag-
onists which show a substantial reduction in post-
prandial glucose excursions, weight and daily insulin
requirements [20, 22, 23]. Sodium–glucose cotransporter
2 (SGLT2) inhibitors provide insulin-independent glu-
cose lowering by inhibiting glucose reabsorption in the
proximal renal tubule. The FDA has warned about the risk
of ketoacidosis occurring in the absence of significant
hyperglycemia in patients receiving these medications;
thus, patients should be counseled on maintaining ad-
equate hydration and monitored for ketoacidosis [20, 24].
Furthermore, patients should be warned that the FDA
recently issued a boxed warning for increased risk for leg
and foot amputation for one SGLT2 inhibitor, Canagliflo-
zin. A clear benefit has not been demonstrated with use of
thiazolidinediones (TZDs) in type 1 patients and the many
potential side effects make it a less appealing option for
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add-on therapy. Use of metformin, GLP-1 agonists, DPP-4
inhibitors, and SGLT2 inhibitors may be considered safe
and effective add-on therapy to insulin although large
clinical trials are needed before routine use in this popula-
tion [20]. Our patient may have benefited from one of
these therapies, which highlights that primary care pro-
viders need a broader understanding of acceptable treat-
ment options for patients with LADA.
A previous autoimmune disease in a given patient
increases the chance of another autoimmune disease in
that same patient, and therefore there should be a low
threshold for screening for concomitant autoimmune
diseases. Screening and regular follow-up should be per-
formed to detect other endocrine deficiencies before the
development of potentially severe acute (such as adrenal
crisis or ketoacidosis) or chronic complications (such as
microvascular damage in type 1 diabetes). Early aware-
ness of patients having LADA may result in more regu-
lar and targeted follow-up and a quicker transition to
insulin if not initiated at diagnosis. The mainstay of ther-
apy is insulin replacement, although tight control with
intensive insulin is challenging. Insulin resistance is
increasingly recognized as a barrier to ideal glycemic
control in LADA, thus non-insulin therapies can be con-
sidered at early diagnosis or more commonly as add-on
to insulin.
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